How effective is Melphalan/Melphalan tablets?

Melphalan/Melphalan is a chemotherapy drug widely used to treat multiple myeloma and certain lymphomas. Melphalan is also widely studied in other types of cancer, such as ovarian cancer and certain types of solid tumors, and although its use in these areas is still in the exploratory stage, preliminary results show its potential.

In the treatment of multiple myeloma, melphalan is commonly used for initial and maintenance treatment. For patients with newly diagnosed multiple myeloma, response rates can be significantly improved by combining melphalan with other drugs, such as corticosteroids or other chemotherapy drugs. Studies have shown that some patients who received melphalan and its combination achieved complete responses, meaning that few cancer cells were detected in the body. However, the rate of complete responses is generally lower than with other novel drug combinations, such as combinations of immunomodulators and targeted agents, but melphalan remains important in certain patient populations.

The efficacy of melphalan is not only reflected in the shrinkage of tumors, but also in the extension of patients' progression-free survival (PFS) and overall survival (OS). Some studies have shown that patients with multiple myeloma treated with melphalan have significantly improved survival. With appropriate treatment, patients can maintain disease-free survival for a longer period of time, which has a positive impact on the patient's quality of life.

However, the therapeutic efficacy of melphalan is also affected by side effects. Common side effects include bone marrow suppression, leading to a decrease in white blood cells, red blood cells, and platelets, which can make patients susceptible to infections, anemia, bleeding, and other problems. Therefore, doctors will closely monitor the patient's blood indicators when using melphalan to ensure that the patient is tolerating the treatment and make necessary adjustments.